

1 **Title: Stereological Estimation and Zonal Distribution of the Hepatotoxic Effects of Doxorubicin on the**
2 **Female Albino Rat (*Rattus Norvegicus*)**

3
4 **Article type:** Original Article

5
6 **Author names:**

- 7 1. Khulud Nurani
- 8 2. Anne Pulei
- 9 3. Beda Olabu
- 10 4. Jeremiah Munguti
- 11 5. Talha Chaudhry
- 12 6. Vincent Kipkorir

13
14 **Degrees and Affiliations:**

- 15 1. BSc Anat. Fourth-year Medical Student. University of Nairobi, Nairobi, Kenya.
- 16 2. BSc Anat, MBChB, MSc. Anat, MMed. (Obs Gyn), MPH, University of Nairobi/Kenyatta National
17 Hospital, Nairobi, Kenya.
- 18 3. BSc Anat, MBChB, MSc. Anat, MMed (Radiology), University of Nairobi/Kenyatta National Hospital,
19 Nairobi, Kenya.
- 20 4. BSc Anat, MBChB, MSc. Anat, University of Nairobi/Kenyatta National Hospital, Nairobi, Kenya.
- 21 5. BSc Anat. Fourth-year Medical Student. University of Nairobi, Nairobi, Kenya.
- 22 6. BSc Anat. Fifth-year Medical Student. University of Nairobi, Nairobi, Kenya.

23
24 **ORCID (Open Researcher and Contributor Identifier):**

- 25 1. <https://orcid.org/0000-0002-0502-0938>
- 26 2. <https://orcid.org/0000-0003-2437-8596>
- 27 3. <https://orcid.org/0000-0003-0782-8006>
- 28 4. <https://orcid.org/0000-0003-4259-2385>
- 29 5. <https://orcid.org/0000-0001-6508-0521>
- 30 6. <https://orcid.org/0000-0001-6946-8857>

31
32 **About the author:** Khulud Nurani is currently a fourth year medical student at The University of Nairobi, Nairobi,
33 Kenya, of a six-year program. She is also a recipient of an Intercalated Degree in Human Anatomy.

34 **Corresponding author email:** khuludnurani@gmail.com

35 **Acknowledgment:** Jimmy Gakure, Felix Mburu, Noel Odero

36
37 **Financing:** Self-funded

38 **Conflict of interest statement by authors:** No conflict of interest

39 **Compliance with ethical standards:** Work covered in this manuscript has been conducted with the ethical
40 approval from The Biosafety, Animal Use and Ethics Committee, Faculty of Veterinary Medicine (Reference
41 Number: FVM BAUEC/2021/286).

1 **Authors Contribution Statement:**

2 Conceptualization, K.N, and T.C.; Methodology, K.N, and T.C.; Investigation, K.N.; Writing – Original Draft, K.N.;
3 Writing – Review & Editing, V.K.; Funding, K.N.; Resources, K.N.; Supervision, A.P., B.O., and J.M.

5 **Manuscript word count:** 2951

6 **Abstract word count:** 247

7 **Number of Figures and Tables:** 8

9 **Personal, Professional, and Institutional Social Network accounts.**

- 10 • **Facebook:**
- 11 • **Twitter:**
- 12 • **Instagram:** khulud.nurani
- 13 • **Linkedin:** [linkedin.com/in/khulud-nurani-99b147179](https://www.linkedin.com/in/khulud-nurani-99b147179)

15 **Discussion Points:**

- 16 • Hepatic Effects of Doxorubicin- An Overlooked Adverse Effect?
- 17 • Doxorubicin Induced Damage to the Hepatic Histoarchitecture
- 18 • What does doxorubicin do to the organization of the liver?
- 19 • Effects of doxorubicin, the first line agent for breast cancer, on the Hepatic Histoarchitecture
- 20 • Double edged effects of doxorubicin in cancer management

22 **Dates**

23 Submission: 10/22/2022

24 Revisions: 04/04/2023, 12/09/2022

25 Responses: 07/20/2023, 01/04/2023

26 Acceptance: 08/06/2023

27 Publication: 08/09/2023

29 **Editors**

30 Associate Editor/Editor: Francisco J. Bonilla-Escobar

31 Student Editors: Amaan Javed, Manas Pustake & Patricio García-Espinosa

32 Copyeditor: Sebastian Diebel

33 Proofreader:

34 Layout Editor:

36 **Publisher's Disclosure:** *This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our readers and authors we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.*

1 **ABSTRACT.**

2 **Background**

3 Doxorubicin is an antineoplastic agent widely indicated for a variety of cancers. One of its adverse effects is
4 hepatotoxicity which presents with hepatocyte necrosis, sinusoidal dilation and fibrosis. However, there remains
5 a dearth in the quantification and zonal distribution of this damage.

6

7 **Methods**

8 Twenty-three adult female Wister albino rats were placed into baseline, control and experimental group
9 receiving 2.5mg/kg bodyweight doxorubicin intra-peritoneally thrice weekly for 3 weeks. Rats were sacrificed on
10 days 0, 7, 14 and 21 and livers harvested for processing. Masson's Trichrome was used in staining 7 μ m thick
11 sections. Images were taken and analyzed via STEPanizer, and data entered into SPSS for analysis.

12

13 **Results**

14 Rats treated with Doxorubicin had increased liver to body weight ratios from 5.00% at baseline to 6.15%, 6.69%
15 and 7.56% on days 7, 14 and 21 ($p=0.090$). There was a decrease in hepatocyte densities from 51.88/mm² to
16 48.61/mm², 46.65/mm² and 42.24/mm² on day 7, 14 and 21 ($p=0.779$). Collagen fiber deposition increased from
17 0.12 \pm 0.06 cm³ to 0.47 \pm 0.55 cm³, 1.64 \pm 0.11 cm³ and 1.88 \pm 0.24 cm³ on days 7, 14 and 21 ($p=0.009$). Deposition
18 was greatest periportally and least pericentrally. Volume of sinusoidal spaces increased from 5.46 \pm 0.50 cm³ to
19 5.49 \pm 0.15 cm³, 5.53 \pm 0.24 cm³ and 5.50 \pm 0.17 cm³ on days 7, 14 and 21 respectively ($p=0.827$). Sinusoids were
20 larger pericentrally than periportally.

21

22 **Conclusion**

23 Doxorubicin administration is associated with an increase in volume density of fibrotic tissue and sinusoidal
24 spaces but decrease in hepatocytes. The quantitative changes presented may facilitate histopathological
25 grading of doxorubicin-induced hepatotoxicity.

26

27 **Key Words:** doxorubicin, hepatotoxicity, liver, stereology

1 **INTRODUCTION.**

2

3 Doxorubicin is a widely indicated antineoplastic agent for a variety of cancers including breast cancer, bladder
4 cancer, thyroid cancer, Kaposi's sarcoma, lymphoma, soft tissue sarcoma, multiple myeloma and acute
5 lymphocytic leukemia. It is the first line agent for metastatic breast cancer as well as for metastatic and locally
6 advanced un-resectable soft-tissue sarcoma.¹ It is administered intravenously in dosage regimens specific to
7 the cancer type and progression.² With regards to its mechanism of action, doxorubicin generates free radicals
8 during its metabolism in the liver. These free radicals disrupt normal cellular physiology and subsequently may
9 cause toxicity in multiple organs mainly in the heart, kidneys and liver.³ Previous studies on Doxorubicin induced
10 hepatotoxicity have been descriptive and remain short of stereological and zonal data.^{4,5}

11

12 Stereology is a growingly applied quantitative method used for the estimation of 3D parameters.⁶ Because 2D
13 profiles do not adequately depict object sizes and quantities, they are prone to inaccuracies when used in
14 morphometric research.⁷ As a result, significant mistakes might be made when interpreting quantitative data
15 from 2D profiles. Stereology provides a solution to this by providing strong mathematical methods to eliminate
16 bias and thus accurately make 3D estimations provided sampling, randomization and isotropy are streamlined.⁸
17 Additionally, quantitative data that can show tiny variations in the volume or number of chosen parameters can
18 be obtained using stereological procedures.⁷ This is of high significance in analysis of liver biopsies which
19 continue to be the gold standard for classifying liver damage.⁹ Consequently, efforts have been made over the
20 past few years to precisely quantify necrotic, fibrotic,¹⁰ steatotic¹¹ and cancerous tissue,¹² both in clinical and
21 experimental studies.¹³ This study, therefore, sought to estimate and zonally determine the distribution of the
22 toxic effects of doxorubicin on the hepatic stroma and parenchyma of the female Albino rat over a 3-week period
23 of Doxorubicin administration.

24

25

26

1 METHODS

2

3 The study was of quasi-experimental design where female albino rats were used. These were obtained from
4 the Department of Zoology and were kept and studied at the Department of Zoology Animal House. The
5 harvested specimens were processed at the Department of Human Anatomy. These rodents were the preferred
6 animal models for research due to their genetic, physiological, and anatomical similarity to humans, ease of
7 maintenance, short life cycle and their small size.¹⁴

8

9 Sample size calculation was done using the formula by Charan & Biswas, 2013¹⁵ using a statistical significance
10 of 0.05, a power of 80%, a smallest meaningful difference of 1.4% and the standard deviation of 0.87% for mean
11 liver fibrosis derived from a study by Yi et al, 2012¹⁶. A total of 23 rats were used of which two were baseline,
12 six were controls and fifteen experimental.

13

14 Ethical approval for the study was sought from the Faculty of Veterinary Medicine (*Reference Number: FVM*
15 *BAUEC/2021/286*). The study was conducted and the animals were handled according to the guidelines
16 provided by the committee.

17

18 Adult female albino rats of three months of age were used in the study upon selection by convenience sampling
19 technique. Doxorubicin's commonest indication is for breast cancer, and breast cancer is more common in
20 females than males, thus female rats were used to account for the protective effects of estrogen on the liver¹⁷.
21 Rats with any visible pathology or abdominal injuries were excluded. The sampling technique involved randomly
22 assigning all the rats a number between 1 and 23 using non-repeating numbers generated by Intel® Digital
23 Random Number Generator Software. The rats were labelled using picric acid on their fur and random selection
24 applied to split them into 3 groups, where group A was the baseline group, Group B was the control group that
25 was administered normal saline intra-peritoneally while group C was the experimental group that was
26 administered Doxorubicin Intra-peritoneally (IP). The rats were housed in standard cages floored with wooden
27 shavings which were replaced every two days. The cages were placed in a room with a normal 12-hour light/dark
28 diurnal cycle. The rats were kept in their cages for 3 days for acclimatization after which intervention was begun.
29 They were provided with standard rat pellets and water ad libitum during the study period. No additional
30 intervention was given to reduce chemotherapy induced distress.

31

32 Each rat in the experimental group received 2.5 mg/kg body weight of Doxorubicin intra-peritoneally thrice
33 weekly for three weeks (at an interval of 48 hours) to correspond with the intravenous route and timeline of
34 administration of Doxorubicin in humans without posing toxicity to the rats. Animals in the control group received
35 zero point five milliliters of normal saline intra-peritoneally thrice weekly as a sham. IP injections were done
36 using a 31-gauge needle to prevent iatrogenic injury.

37

38 Tissue harvesting was done after weighing the rats using an electric measuring scale and euthanizing them by
39 placing them in sealed containers with 1% halothane (1-3%) soaked in cotton wool. Death was confirmed by
40 the absence ocular reflexes. Then a longitudinal incision in the midline of the body was made and normal saline
41 used to flush out all the blood. Thereafter, 10% formal saline was infused by the trans-cardiac method to start

1 tissue fixation. The liver was harvested from each rat, absolute volumes calculated using Scherle's method and
2 stored in formal saline. Systematic uniform random sampling method was used to get the liver segments. The
3 liver was sliced across the lobes into 16 equal parts. The parts were rearranged into a diamond shape with
4 smaller pieces arranged on either side of the largest piece of liver⁹. Following this, the 2nd piece was selected
5 and thereafter every 3rd piece. A total of 5 pieces per liver were picked for histological processing.

6
7 The liver pieces obtained were placed in specimen bottles containing 10% formalin for at least 24 hours in order
8 to preserve the tissues. Following fixation, they were dehydrated in ascending concentrations of alcohol, then
9 cleared in toluene then infiltrated with paraffin wax. The embedded tissues were blocked for sectioning. They
10 were cut into 7 µm thick sections. Every fourth section of the ribbon was selected and floated in a warm water
11 bath to enhance spreading. The sections were fished from the water bath onto a gelatinized glass slide. They
12 were dried at 38°C for 24 hours, then de-waxed, re-hydrated and stained using Masson's Trichrome.

13
14 Out of the 10 stained sections, 5 even sections were chosen for histomorphometric analysis. Photomicrographs
15 were taken at x400 magnification using a Richter Optica™ digital photomicroscope (Model UX1) connected to
16 Motic Images Plus 3.0 for stereological analysis. Three images were taken per slide- one of the periportal region,
17 one of the midzonal region and one of the pericentral region. The photomicrographs were analyzed using
18 STEPanizer Stereology Tool Version 1.0. **The** estimation of volume densities and hepatocyte densities was
19 done using Cavalieri's principle of point counting ⁸. The histological regions were analyzed using a
20 superimposed 100-point grid over the photomicrographs (Figure 1). The volume densities of the histological
21 components were calculated and averaged in order to reduce bias. Absolute volumes were then calculated by
22 multiplying the volume densities with the liver volumes.

23
24 Data obtained were keyed into the Statistical Package for Social Sciences software (version 28.0) for statistical
25 analysis. Hepatocytes were expressed in numbers/mm² and fibrotic tissue and sinusoidal spaces were
26 expressed as absolute volumes. The data were grouped into three groups: A, B and C. The Shapiro-Wilk test
27 and a visual examination of the histograms and box plots produced from the data were used to determine
28 whether the data were normal. Although the Shapiro Wilk test indicated a normal distribution, the histograms
29 displayed skewed distributions. Thus, non-parametric tests were employed. Kruskal Wallis test was employed
30 to check for statistically significant differences over time in both the control and experimental groups over the
31 study period. A Dunn Bonferroni post-hoc test was carried out. Mann Whitney U tests were carried out to assess
32 for significant differences between the control and experimental group on each of the perfusion days. A p value
33 of 0.05 or lower was regarded as significant. Photomicrographs were used to demonstrate the histological
34 findings.

35

1 RESULTS.

2 General health of Study Animals

3 Following Doxorubicin administration, the study animals developed diarrhea, roughness in their fur coat,
4 mucosal inflammation and tremors. They exhibited hypoactivity and reduced food intake. No discernible gross
5 changes in livers of the experimental rats were noted when compared to the control and the baseline groups.
6

7 Liver to Body Weight Ratio (LBWR)

8 The liver to body weight ratios of the control animals increased slightly over time ($p=0.180$) with those of the
9 experimental animals increasing more rapidly ($p=0.090$). The difference in LBWR between controls and
10 experimental groups was statistically significant ($p=0.029$).
11

12 Collagen fiber density

13 Doxorubicin administration resulted in deposition of collagen fibers in the periportal areas as well as within
14 perisinusoidal spaces that increased with time ($p=0.009$). This is illustrated in Figures 2 and 3 below. Bridging
15 fibrosis also developed and was most defined on day 21. In contrast, the stroma of the control group hardly had
16 any differences in collagen fiber volumes from baseline tissues. The experiment and control groups thus, had
17 statistically significant differences in collagen fiber volumes ($p<0.001$). Table 1 displays the means, standard
18 deviations, medians, interquartile ranges and p values of the control and experimental groups over time.
19

20 Sinusoidal space density

21 Doxorubicin administration resulted in an increase in volumes of sinusoidal spaces over time ($p=0.827$). This is
22 illustrated in Figure 4 below. Sinusoids in the pericentral area were larger than those in periportal areas. In
23 contrast, sinusoids in control tissue did not have distinct differences in sinusoidal densities from baseline tissue
24 ($p=1.000$). The experimental and controls groups did not have statistically significant differences in sinusoidal
25 volumes ($p=0.667$). Table 2 displays the means, standard deviations, medians, interquartile ranges and p values
26 of the control and experimental groups over time
27

28 Effects of Doxorubicin on the Hepatic Parenchyma

29 The control rats displayed normal liver histoarchitecture. However, the experimental rats had distortions in their
30 parenchyma. There was marked degeneration with disruption of the cord-like arrangement of hepatocytes.
31 There was also infiltration of deeply basophilic leukocytes in the periportal area and regions of focal necrosis in
32 the pericentral area. The hepatocytes nearer the central veins were more vacuolated than those in the periportal
33 areas.
34

35 Hepatocyte densities declined progressively with minimum numbers recorded in the 3rd week ($p=0.779$). This
36 is illustrated in Figure 5 below. The periportal areas had a higher concentration of hepatocytes relative to the
37 pericentral areas. On the other hand, hepatocyte densities for the control rats remained similar in number to
38 those in baseline tissue ($p=0.867$). The differences between control and experimental values were however,
39 not statistically significant ($p=0.178$). Table 3 displays the means, standard deviations, medians, interquartile
40 ranges and p values of the control and experimental groups over time (Table 3).
41
42

1 **DISCUSSION.**

2 The findings in this study are suggestive of a temporal increase in the deposition of collagen fibers and in
3 sinusoidal dilatation but decrease in hepatocyte densities as discussed below. These structural changes may
4 be helpful in grading of toxicity via liver biopsies, provide clarity on the zonal distribution of structural changes,
5 and pave way for studies to determine strategies to reduce the severity of Doxorubicin induced hepatotoxicity.

6

7 **General health of Study Animals**

8 The experimental rats in this study developed diarrhea, roughness in their fur coat, mucosal inflammation and
9 tremors. These effects may be due to an inhibition of multiplication of otherwise rapidly proliferating cells of the
10 gastrointestinal tract, skin and bone marrow by doxorubicin ¹⁸.

11

12 **Liver to Body Weight Ratio**

13 Doxorubicin treatment resulted in an increase in the LBWR compared to that of the control rats. The increase
14 in liver weight observed in this study following Doxorubicin is similar to the findings by Salouge et al., (2014)
15 who found an increase in organ to body weight ratios of the heart, liver, spleen and kidneys following Doxorubicin
16 administration in rats. The increase in liver weights corresponds to augmentative hepatomegaly which is a
17 compensatory regenerative process following hepatocyte necrosis ²⁰. The initial phase of hepatomegaly is
18 hypertrophy of the existing hepatocytes then later hyperplasia if regeneration is still incomplete. In this study,
19 hypertrophy of hepatocytes could explain the increase in LBWR since a reduction in hepatocyte densities
20 precluding regenerative hyperplasia of hepatocytes was observed. Hepatomegaly is a common adverse effect
21 of chemotherapy and may culminate in severe liver injury and even liver failure if not controlled ²¹.

22

23 **Collagen Fiber Density**

24 Doxorubicin administration resulted in an increase in collagen fiber deposition in the perisinusoidal and
25 periportal areas over time. Perisinusoidal fibrosis is postulated as being a result of hepatocyte stellate cell (HSC)
26 activation by the reactive oxygen species (ROS) released during Doxorubicin metabolism. The activated HSC
27 transform into highly proliferative myofibroblasts-like cells with a greatly enhanced capacity to synthesize ECM
28 components including type I and III fibrillary collagen, laminins and fibronectin²². The periportal and bridging
29 fibrosis may be due to the activation of portal fibroblasts to form portal myofibroblasts which are pronounced for
30 their matrix deposition and contractility ²³. Placement of groups of contractile cells in collagen type I matrices
31 leads to compaction and alignment of the collagen between them, creating the appearance of bridging fibrosis.
32 This may explain the realignment of connective tissue fibers seen in bridging fibrosis. Advancing of liver fibrosis
33 may result in nodular regeneration, cirrhosis, and portal hypertension and often requires liver transplantation ²².

34

35 **Sinusoidal Space Dilation**

36 Doxorubicin administration resulted in an increase in the sinusoidal space density. Injury to sinusoidal
37 endothelial cells by ROS leads to embolization of endothelial cells and blood cells in sinusoidal spaces. This
38 blocks venous outflow, resulting in hepatic congestion and subsequent sinusoidal dilatation. This is followed by
39 sinusoidal obstruction syndrome characterized by fiber deposition in the sinusoids by activated HSC and
40 obliteration of central venules²⁴. The result is the loss of fenestrations and development of basement
41 membranes by sinusoidal endothelial cells in a process of capillarization, forming channels with larger calibers²⁵.

1 Sinusoidal obstruction syndrome can progress into regenerative nodular hyperplasia or may normalize with time
2 after cessation of chemotherapy²¹. Sinusoidal obstruction causes congestion, hepatomegaly, fluid retention,
3 jaundice and ascites, and becomes fatal in 20-50% of patients on high dose chemotherapy²⁶.

5 **Effects of Doxorubicin on the Hepatic Parenchyma**

6 Periportal leukocyte infiltration following doxorubicin administration as observed in this study may due to an
7 increase in recruitment of immune cells via chemotaxis following hepatocyte injury and death²⁷. Hepatocyte
8 vacuolation following Doxorubicin administration as observed in this study, was associated with larger nuclei,
9 and is postulated as being a marker of senescence. It is present in a variety of acute and chronic liver diseases.
10 However, the exact pathophysiology behind the vacuolation is unclear and is suggested as being the result of
11 hydropic change²⁸. Focal necrosis, in association with lymphocytes, as observed in this study, describes a
12 continuum of lobular injury²⁹.

13
14 Decrease in hepatocytes following doxorubicin administration as observed in this study, may be a result of
15 hepatocyte necrosis and apoptosis. The FR released during doxorubicin metabolism reacts with hepatocyte
16 lipids, proteins and nuclei acids causing mitochondrial dysfunction and lipid peroxidation which induces
17 apoptosis. Following cell death, regeneration of hepatocytes is also impaired as doxorubicin inhibits
18 topoisomerase II activity and thus inhibiting cell division³⁰. The result is a decline in hepatocyte numbers and
19 distortion in the radial organization of cords. Severe hepatocyte apoptosis and necrosis may culminate into liver
20 failure.

22 **Limitations and Delimitations**

23 This study may have had some possible confounders such as inter-animal differences in the absorption and
24 metabolism of doxorubicin. This was, however, minimized by the use of in-bred rats which are genetically
25 similar. Also, stress due to intraperitoneal injections may have affected the hepatic histoarchitecture. This was
26 standardized by the administration of normal saline intraperitoneal injections in the control group. In addition,
27 tissue shrinkage during tissue processing may have altered the normal parameters. However, errors due to
28 tissue processing were carried through all measurements.

30 **Strengths of the Study**

- 31 1. The histoarchitecture of the Albino rat liver very closely resembles that of humans.
- 32 2. Intermittent dosage forms administered make it analogous to Doxorubicin therapy in humans.
- 33 3. Sacrifice at the end of each week enabled establishment of temporal effects

35 **Conclusion**

36 Doxorubicin administration is associated with an increase in the volume densities of fibrotic tissue and sinusoidal
37 spaces, and decrease in hepatocyte densities. The quantitative structural changes further corroborate
38 Doxorubicin-induced hepatotoxicity and may facilitate histopathological diagnosis of hepatotoxicity.

1 **SUMMARY - ACCELERATING TRANSLATION**

2 **Title**

3 Stereological Estimation and Zonal Distribution of the Hepatotoxic Effects of Doxorubicin on the Female Albino
4 Rat (*Rattus Norvegicus*)

6 **Main Problem**

7 Doxorubicin is a chemotherapeutic agent widely indicated for a variety of cancers. One of its side effects is liver
8 toxicity which presents with cellular death, vascular dilation and fibrosis. However, there has remained a dearth
9 in the quantification and zonal distribution of this liver damage.

10

11 **Aim**

12 To quantify and zonally determine the distribution of the hepatotoxic effects of doxorubicin on the female
13 Albino rat

14

15 **Methodology**

16 Twenty-three adult female Wister albino rats were placed into 3 groups: baseline, control and experimental. The
17 experimental group received 2.5mg/kg bodyweight of doxorubicin intra-peritoneally thrice weekly for 3 weeks.
18 The control group received 0.5 ml normal saline intra-peritoneally thrice weekly as a sham. Rats were then
19 sacrificed on days 0, 7, 14 and 21 and their livers harvested for processing and analysis.

20

21 **Results**

22 Rats treated with Doxorubicin had increased liver to body weight ratios from 5.00% at baseline to 6.15%, 6.69%
23 and 7.56% on days 7, 14 and 21 ($p=0.090$). There was a decrease in hepatocyte densities from 51.88/mm² to
24 48.61/mm², 46.65/mm² and 42.24/mm² on day 7, 14 and 21 ($p=0.779$). Collagen fiber deposition increased from
25 0.12±0.06 cm³ to 0.47±0.55 cm³, 1.64±0.11 cm³ and 1.88±0.24 cm³ on days 7, 14 and 21 ($p=0.009$). Deposition
26 was greatest periportally and least pericentrally. Volume of sinusoidal spaces increased from 5.46±0.50 cm³ to
27 5.49±0.15 cm³, 5.53±0.24 cm³ and 5.50±0.17 cm³ on days 7, 14 and 21 respectively ($p=0.827$). Sinusoids were
28 larger pericentrally than periportally.

29

30 **Conclusion**

31 Doxorubicin administration is associated with an increase in volume density of fibrotic tissue and sinusoidal
32 spaces but decrease in hepatocyte densities. The quantitative changes presented may facilitate
33 histopathological grading of doxorubicin-induced hepatotoxicity.

34

35

36

37

38

39

40

41

1 **REFERENCES.**


- 2 1. Paridaens R, Biganzoli L, Bruning P, Klijn JGM, Gamucci T, Houston S, et al. Paclitaxel Versus
3 Doxorubicin as First-Line Single-Agent Chemotherapy for Metastatic Breast Cancer: A
4 European Organization for Research and Treatment of Cancer Randomized Study With Cross-
5 Over. *J Clin Oncol.* 2000;18(4):724–724.
- 6 2. Johnson-Arbor K, Dubey R. Doxorubicin. In: StatPearls. Treasure Island (FL): StatPearls
7 Publishing. Available from: <http://www.ncbi.nlm.nih.gov/books/NBK459232/>. Cited 2021 Jun
8 15.
- 9 3. Thorn CF, Oshiro C, Marsh S, Hernandez-Boussard T, McLeod H, Klein TE, et al. Doxorubicin
10 pathways: pharmacodynamics and adverse effects. *Pharmacogenet Genomics.* 2011;21(7):440–
11 6.
- 12 4. Al-Qzazz MM, Al-Sammak MA, Taher MT. Effect of Doxorubicin on the Histological Structure
13 of the Liver in Male Albino Rats = تأثير عقار الدوكسوروبسين على التركيب النسيجي لكبد الجرذان. *Jordan Med*
14 *J.* 2013;47(3):220–6.
- 15 5. Al-Saleem IA, Jumaa HJ, Al-Ani IM, Ismael HK. Morphological Changes in the Liver of Rats
16 (*Rattus norvegicus*) treated with different Doses of Doxorubicin. 2017;16:9.
- 17 6. Kipanyula MJ, Sife AS. Global Trends in Application of Stereology as a Quantitative Tool in
18 Biomedical Research. *BioMed Res Int.* 2018;2018:1–9.
- 19 7. Marcos R, Monteiro RAF, Rocha E. The use of design-based stereology to evaluate volumes and
20 numbers in the liver: a review with practical guidelines: Design-based stereology in hepatology.
21 *J Anat.* 2012 Apr;220(4):303–17.
- 22 8. Mandarim-de-Lacerda CA. Stereological tools in biomedical research. *An Acad Bras Ciênc.*
23 2003;75(4):469–86.
- 24 9. Marcos R, Bragança B, Fontes-Sousa AP. Image Analysis or Stereology: Which to Choose for
25 Quantifying Fibrosis? *J Histochem Cytochem.* 2015;63(9):734–6.
- 26 10. Vertemati M, Minola E, Goffredi M, Sabatella G, Gambacorta M, Vizzotto L. Computerized
27 morphometry of the cirrhotic liver: Comparative analysis in primary biliary cirrhosis, alcoholic
28 cirrhosis, and posthepatitic cirrhosis. *Microsc Res Tech.* 2004;65(3):113–21.
- 29 11. Catta-Preta M, Mendonca LS, Fraulob-Aquino J, Aguila MB, Mandarim-de-Lacerda CA. A
30 critical analysis of three quantitative methods of assessment of hepatic steatosis in liver biopsies.
31 *Virchows Arch.* 2011;459(5):477–85.
- 32 12. Vertemati M, Vizzotto L, Moscheni C, Dhillon A, Dhillon A, Quaglia A. A morphometric model
33 to minimize subjectivity in the histological assessment of hepatocellular carcinoma and its
34 precursors in cirrhosis. *Microsc Res Tech.* 2008;71(8):606–13.
- 35 13. Dahab GM, Kheriza MM, El-Beltagi HM, Fouda AMM, El-Din OAS. Digital quantification of
36 fibrosis in liver biopsy sections: Description of a new method by Photoshop software. *J*
37 *Gastroenterol Hepatol.* 2004;19(1):78–85.

- 1 14. Vdovíaková K, Vdovíaková K, Petrovová E, Krešáková L, Maloveská M, Teleky J, et al.
2 Importance Rat Liver Morphology and Vasculature in Surgical Research. *Med Sci Monit.*
3 2016;22:4716–28.
- 4 15. Charan J, Biswas T. How to Calculate Sample Size for Different Study Designs in Medical
5 Research? *Indian J Psychol Med.* 2013;35(2):121–6.
- 6 16. Yi E tong, Liu R xia, Wen Y, Yin C hong. Telmisartan attenuates hepatic fibrosis in bile duct-
7 ligated rats. *Acta Pharmacol Sin.* 2012 Dec;33(12):1518–24.
- 8 17. Ly D, Forman D, Ferlay J, Brinton LA, Cook MB. An international comparison of male and
9 female breast cancer incidence rates. *Int J Cancer.* 2013;132(8):1918–26.
- 10 18. Mitchison TJ. The proliferation rate paradox in antimetabolic chemotherapy. Kellogg D. *Mol Biol*
11 *Cell.* 2012;23(1):1–6.
- 12 19. Salouge I, Ali R, Saïd D, Elkadri N, Kourda N, Lakhali M, et al. Means of evaluation and
13 protection from doxorubicin-induced cardiotoxicity and hepatotoxicity in rats. *J Cancer Res Ther.*
14 2014;10(2):274.
- 15 20. Michalopoulos GK. Principles of liver regeneration and growth homeostasis. *Compr Physiol.*
16 2013 Jan;3(1):485–513.
- 17 21. Maor Y, Malnick S. Liver Injury Induced by Anticancer Chemotherapy and Radiation Therapy.
18 *Int J Hepatol.* 2013;2013:1–8.
- 19 22. Bataller R, Brenner DA. Liver fibrosis. *J Clin Invest.* 2005 Feb;115(2):209–18.
- 20 23. Forbes SJ, Parola M. Liver fibrogenic cells. *Best Pract Res Clin Gastroenterol.* 2011
21 Apr;25(2):207–17.
- 22 24. Sharma A, Houshyar R, Bhosale P, Choi JI, Gulati R, Lall C. Chemotherapy induced liver
23 abnormalities: an imaging perspective. *Clin Mol Hepatol.* 2014;20(3):317.
- 24 25. Brancatelli G, Furlan A, Calandra A, Dioguardi Burgio M. Hepatic sinusoidal dilatation. *Abdom*
25 *Radiol.* 2018;43(8):2011–22.
- 26 26. Fan CQ, Crawford JM. Sinusoidal obstruction syndrome (hepatic veno-occlusive disease). *J Clin*
27 *Exp Hepatol.* 2014 Dec;4(4):332–46.
- 28 27. El-Sayyad HI, Ismail MF, Shalaby FM, Abou-El-Magd R, Gaur RL, Fernando A, et al.
29 Histopathological effects of cisplatin, doxorubicin and 5-fluorouracil (5-FU) on the liver of male
30 albino rats. *Int J Biol Sci.* 2009;466–73.
- 31 28. Nayak NC, Sathar SA, Mughal S, Duttgupta S, Mathur M, Chopra P. The nature and significance
32 of liver cell vacuolation following hepatocellular injury? An analysis based on observations on
33 rats rendered tolerant to hepatotoxic damage. *Virchows Arch.* 1996;428(6).
- 34 29. Krishna M. Patterns of necrosis in liver disease: Patterns of Necrosis in Liver Disease. *Clin Liver*
35 *Dis.* 2017;10(2):53–6.
- 36 30. Box VGS. The intercalation of DNA double helices with doxorubicin and nagalomycin. *J Mol*
37 *Graph Model.* 2007;26(1):14–9.

1 **FIGURES AND TABLES.**


2

3 **Figure 1. STEPanizer Grid for Estimation of Volume Densities**



4

5 **Figure 2. Collagen Fiber Profile in Rat Livers**



6

1 **LEGEND:**

2 **Figure 2A-F:** Collagen Fiber Profile in the Rat Livers. Stain: Masson's Trichrome, Magnification: X 400.

3

4 **Figure 2A:** Photomicrograph of the liver of a control rat on day 7 of the study. There are a few collagen fibers
5 (yellow arrows) interspersed between the hepatocytes in the perisinusoidal spaces. The black arrows point at
6 collagen fibers around the portal triad.

7

8 **Figure 2B:** Photomicrograph of the liver of a rat treated with Doxorubicin on day 7 of the study. There are a few
9 collagen fibers (yellow arrows) interspersed between the hepatocytes in the perisinusoidal spaces. The black
10 arrows point at collagen fibers around the portal triad.

11

12 **Figure 2C:** Photomicrograph of the liver of a control rat on day 14 of the study. There are a few collagen fibers
13 (yellow arrows) interspersed between the hepatocytes in the perisinusoidal spaces. The black arrows point at
14 collagen fibers around the portal triad.

15

16 **Figure 2D:** Photomicrograph of the liver of a rat treated with Doxorubicin on day 14 of the study. There are
17 collagen fibers (yellow arrows) interspersed between the hepatocytes in the perisinusoidal spaces. The black
18 arrows point at collagen fibers around the portal triad.

19


20 **Figure 2E:** Photomicrograph of the liver of a control rat on day 21 of the study. There are a few collagen fibers
21 (yellow arrows) interspersed between the hepatocytes in the perisinusoidal spaces. The black arrows point at
22 collagen fibers around the portal triad.

23

24 **Figure 2F:** Photomicrograph of the liver of a rat treated with Doxorubicin on day 21 of the study. There are more
25 collagen fibers (yellow arrows) interspersed between the hepatocytes in the perisinusoidal spaces. The black
26 arrows point at collagen fibers around the portal triad.

27

28 **Figure 3:** Comparison of Bridging Fibrosis in Control and Experimental Rat Livers



LEGEND: Figure 3A-F: Bridging Fibrosis in the Rat Livers. Stain: Masson's Trichrome, Magnification: X 400.

Figure 3A: Photomicrograph of the liver of a control rat treated on day 7 of the study. There was no bridging fibrosis. Only some collagen fibers were present around the portal triad

Figure 3B: Photomicrograph of the liver of a rat treated with Doxorubicin on day 7 of the study demonstrating setting in of bridging fibrosis (black arrows).

Figure 3C: Photomicrograph of the liver of a control rat on day 14 of the study demonstrating some bridging fibrosis (black arrows).


Figure 3D: Photomicrograph of the liver of a rat treated with Doxorubicin on day 14 of the study demonstrating some bridging fibrosis (black arrows).

Figure 3E: Photomicrograph of the liver of a control rat on day 21 of the study demonstrating some bridging fibrosis (black arrows).

1 **Figure 3F:** Photomicrograph of the liver of a rat treated with Doxorubicin on day 21 of the study demonstrating
2 the most extensive bridging fibrosis (black arrows).

3

4 **Figure 4:** Comparison of Sinusoidal Spaces in Control and Experimental Rat Livers



5

6 **LEGEND: Figure 4A-F:** Sinusoidal Spaces in the Rat Livers. Stain: Masson's Trichrome, Magnification: X 400.

7

8 **Figure 4A:** Photomicrograph of the liver of a control rat on day 7 of the study. The relatively small sinusoidal
9 spaces are illustrated with black arrows.

10

11 **Figure 4B:** Photomicrograph of the liver of a rat treated with Doxorubicin on day 7 of the study. There are
12 relatively larger sinusoidal spaces (Black arrows).

13

14 **Figure 4C:** Photomicrograph of the liver of a control rat on day 14 of the study. Sinusoidal spaces, pointed at
15 by black arrows, are smaller than those in Figure 9D.

16

17 **Figure 4D:** Photomicrograph of the liver of a rat treated with Doxorubicin on day 14 of the study. There are
18 larger and more distorted sinusoidal spaces (Black arrows).

19

1 **Figure 4E:** Photomicrograph of the liver of a control rat on day 21 of the study. Sinusoidal spaces, pointed at
2 by black arrows, are smaller than those in Figure 9F.

3

4 **Figure 4F:** Photomicrograph of the liver of a rat treated with Doxorubicin on day 21 of the study. Sinusoidal
5 spaces, pointed at by black arrows, are the largest and most distorted.

6

7 **Table 1.** Volume of Fibrotic Tissue at different time periods

Day	Group	Volume of Fibrosis (cm ³)	
		Mean ± SD	Median (IQR)
0	Baseline	0.12 ± 0.08	0.12
7	Control	0.14 ± 0.03	0.14
	Experimental	0.47 ± 0.12	0.45 (0.36-0.59)
14	Control	0.13 ± 0.06	0.13
	Experimental	1.64 ± 0.24	1.54 (1.50-1.83)
21	Control	0.17 ± 0.11	0.17
	Experimental	1.88 ± 0.55	1.97 (1.37-2.35)

8

9 **Table 2.** Volume of Sinusoidal Spaces at different time periods

10

Day	Group	Sinusoidal Spaces (cm ³)		P value (vs control) Exact Sig. [2*(1-tailed Sig.)]
		Mean± SD	Median (IQR)	
0	Baseline	5.46 ± 0.70	5.46	-
7	Control	5.14 ± 0.56	5.44	1.000
	Experimental	5.49 ± 0.34	5.52 (5.15-5.80)	
14	Control	5.15 ± 0.21	5.45	0.857
	Experimental	5.50 ± 0.54	5.67 (5.04-5.95)	
21	Control	5.14 ± 0.45	5.44	0.857
	Experimental	5.50 ± 0.39	5.40 (5.18-5.88)	


11

1 **Table 3. Hepatocyte area densities at different time periods**

Day	Group	Hepatocyte area densities (no./counting area)		P value (vs control) Exact Sig. [2*(1- tailed Sig.)]
		Mean \pm SD	Median (IQR)	
0	Baseline	11.41 \pm 2.24	11.41	-
7	Control	11.32 \pm 1.09	11.32	0.571
	Experimental	10.69 \pm 1.03	10.56 (9.74-11.71)	
14	Control	11.28 \pm 0.16	11.27	0.381
	Experimental	10.26 \pm 0.65	10.13 (9.71-10.88)	
21	Control	11.05 \pm 0.72	11.05	0.857
	Experimental	9.29 \pm 4.43	6.52 (5.85-14.12)	

2
3

4 **Figure 5. Change in hepatocyte densities over time**



5
6
7
8